Muhammad M. Mohiuddin, MBBS

Education

1989 MBBS (MD), Medicine, Dow Medical College, Karachi, Pakistan

2023 DSc (Hon), Dow University of Health Sciences, Karachi, Pakistan

Postdoctoral Education and Training

1990-1991 Residency, Civil Hospital (Medicine & Surgery), Karachi, Pakistan

1991-1993 Fellowship, Transplantation Biology and Immunology, Department of Cardiothoracic Surgery Harrison Department of Surgical Research, University of Pennsylvania Medical Center, Philadelphia, PA

1993-1998 Fellowship, Transplantation Surgery, Department of Cardiothoracic Surgery, MCP-Hahnemann Medical School (Allegheny University), Philadelphia, PA

1997-1998 Fellowship, Bone marrow Transplantation, Institute for Cellular Therapeutics, Allegheny university of the Health Sciences, Philadelphia, PA

2003-2005 Fellowship, Human Islet Transplantation, University of Pennsylvania, Philadelphia, PA

Dr Mohiuddin previously served as Chief of Transplantation of the Cardiothoracic Surgery Research Program at the National Heart Lung and Blood Institute / the National Institutes of Health (NIH). He held faculty positions at the University of Pennsylvania, Philadelphia, and Rush University, Chicago.

He has been involved in Xenotransplantation Research since 1991 and started xenotransplantation research programs at the NIH, Rush University Chicago, and University of Maryland School of Medicine.

He is Associate Editor for Transplantation and reviews manuscripts for many other journals. He is also the past president of the Dow Graduate Association of North America. Achievements include several NIH and non-NIH grants during his academic career. He is a member of the Community of Transplant Scientists (COTS) executive committee and the advisory council of transplant regenerative medicine of the American Society of Transplantation (AST). He has been elected a the fellow of American Society of Transplantation (FAST). 

Dr. Mohiuddin has devoted his entire career to Xenotransplantation. His contribution to Xenotransplantation includes the demonstration of the most prolonged survival in heterotopic and orthotopic cardiac Xenotransplantation. He is currently President of the International Xenotransplantation Association (IXA) after serving as Councilor for 4 years and as liaison to promote productive dialogue between the IXA and the FDA. He has published over 120 papers, and more than 150 abstracts. Additionally, he has been an invited Xenotransplantation expert speaker on numerous occasions.

His persistence in Xenotransplantation directed him to accomplish the First Genetically Engineered Pig to Human Cardiac Xenotransplantation on January 7, 2022. He also led the 2^nd xenotransplantation procedure on September 2023. Both surgeries are performed at the University of Maryland Medical Center, Baltimore, Maryland.

Dr Mohiuddin has been awarded a honorary degree of Doctor of Science (DSC) degree by the Dow University of Health Sciences.

Besides other awards, Dr Mohiuddin was picked by Nature Journal as one of the “Nature’s 10” in 2022. Ten people who helped shape science in 2022.

Dr Mohiuddin was honored by National Geographic Magazine in 2025 in their NatGeo33 issue as one of the 10 Global Visionaries who are Bold leaders pursuing imaginative ideas to make meaningful impact

Cardiac xenotransplantation, immunosuppressive therapy, surgical procedures in large and small animal models, B cell immunology, immunomodulation, bone marrow transplantation

Griffith BP, Grazioli A, Singh AK, Tully A, Galindo J, Saharia KK, Shah A, Strauss ER, Odonkor PN, Williams B, Silverman HJ, Burke A, Drachenberg CB, Wells CL, Dickfeld T, Hong SN, Hicks AJ 3rd, Ananthram M, Gupta A, Christenson RH, Tamburro L, Zhang T, Hershfeld A, Lewis B, Feller ED, Kuravi K, Sorrells L, Morgand E, Mezine F, Goutaudier V, Rothblatt M, Lau CL, Taylor B, Perrin S, Loupy A, Ayares D, Mohiuddin MM. Transplantation of a genetically modified porcine heart into a live human. Nat Med. 2025 Feb;31(2):589-598. doi: 10.1038/s41591-024-03429-1. Epub 2025 Jan 8. PMID: 39779924.

Singh AK, Goerlich CE, Zhang T, Lewis B, Hershfeld A, Braileanu G, Kurvi K, Rice K, Sentz F, Mudd S, Odonkor P, Strauss E, Williams B, Burke A, Gupta A, Drachenberg CB, Ayares D, Griffith BP, Mohiuddin MM. Genetically engineered pig heart transplantation in non-human primates. Commun Med (Lond). 2025 Jan 7;5(1):6. doi: 10.1038/s43856-025-00731-y. PMID: 39774817; PMCID: PMC11707197.

Mohiuddin MM, Singh AN, Scobie L, Goerlich C, et al. Graft dysfunction in compassionate use of genetically engineered pig-to-human cardiac xenotransplantation: a case report The Lancet DOI:10.1016/S0140-6736(23)00775-4 June 2023 

Griffith BP, Goerlich CE, Singh AK, Rothblatt M, Lau C, Shah A, Lorber M, Grazioli A, Saharia K, Hong S, Joseph S, Ayares D, Mohiuddin MM. Genetically Modified Pig-To-Human Cardiac Xenotransplantation. New England Journal of Medicine. June 2022

Goerlich C, Griffith BP, Shah A, Treffalls J, Zhang T, Mohiuddin MM, et al. A Standardized Approach to Orthotopic (Life-supporting) Porcine Cardiac Xenotransplantation in a Nonhuman Primate Model Transplantation DOI: 1097/TP.0000000000004508 January 2023

Singh AK, Goerlich C, Zhang T, Lewis BG, Hershfeld A, Mohiuddin MM. CD40-CD40L. Blockade: Update on Novel Investigational Therapeutics for Transplantation Transplantation DOI: 1097/TP.0000000000004469 December 2022

Mohiuddin MM, Goerlich CE, Singh AK, et al. Progressive Genetic Modifications of Porcine Cardiac Xenografts Extend Survival to 9 Months. Xenotransplantation; Wiley Online; March 2022

Mohiuddin MM, Singh A, Goerlich C. Preclinical rational and current pathways to support the first human clinical trials in cardiac xenotransplantation Human Immunology DOI:10.1016/j.humimm.2022.07.001 July 2022

Mohiuddin MM, Singh A, Goerlich C. Preclinical rational and current pathways to support the first human clinical trials in cardiac xenotransplantation Human Immunology DOI:10.1016/j.humimm.2022.07.001 July 2022

Mohiuddin MM, Singh AK, Corcoran PC, Thomas ML, Clark T, Lewis BG, Hoyt RF, Eckhaus M, Pierson RN, Belli AJ, Wolf E, Klymiuk N, Phelps C, Reimann KA, Ayares D, Horvath KA. Chimeric 2C10R4 anti-CD40 antibody therapy is critical for long-term survival of GTKO. hCD46. hTBM pig-to-primate cardiac xenograft. Nature Communications. 2016 Apr 5;7:a11138. doi: 10.1038/ncomms11138.

Mohiuddin MM, Singh AK, Corcoran PC, Hoyt RF, Thomas ML, Ayares D, Horvath KA. Genetically engineered pigs and target-specific immunomodulation provide significant graft survival and hope for clinical cardiac xenotransplantation. The Journal of Thoracic and Cardiovascular Surgery. 2014 Sep; 148(3): 1106-1114.

Porter CM, Horvath‐Arcidiacono JA, Singh AK, Horvath KA, Bloom ET, Mohiuddin MM. Characterization and expansion of baboon CD4+ CD25+ Treg cells for potential use in a non‐human primate xenotransplantation model. Xenotransplantation. 2007 Jul 28; 14(4): 298-308.

Mohiuddin MM, Ogawa H, Yin D, Shen J, Galili U. Antibody-mediated accommodation of heart grafts expressing an incompatible carbohydrate antigen. Transplantation. 2003 Feb 15; 75(3): 258-262.

Mohiuddin MM. Clinical xenotransplantation of organs: why aren't we there yet? PLOS Medicine 4(3): e75. 2007 Mar 27; PubMed PMID: 0040075.